CurieCoreTech CRISPR'it Genetic Screening
The last decade has seen the emergence of new genome modification technologies. Published in 2012, the CRISPR/Cas9 system, that granted Emmanuelle Charpentier and Jennifer Doudna with Chemistry Nobel Prize in 2020, allows by its great flexibility, the individual inactivation of all known genes by targeted cutting of the DNA.
Monday, September 26th 2022
09:30 am
Le Pharo, Marseille Le pharo
«1 Day meeting : CRISPR Screening in Cancer Discovery»
Co-organised by CRISPR'it core facility (Curie) and CRISPR Action (Marseille-Nice), this first edition of the meeting will bring together an outstanding line-up of speakers in functional genomics which will cover the use of CRISPR-Cas9 screening tools for the understanding of the genetic mechanisms underlying tumor growth, the discovery of new therapeutic avenues including immunotherapies and the development of state-of-the-art approaches allowing CRISPR screens in vivo, in 3D or combined with single-cell transcriptomics. There will be several opportunities for young scientists to present their work through selected talks and posters.
Program
https://siric.curie.fr/sites/siric/files/medias/documents/2022-07/CRISPR%20Preliminary%20Agenda.pdf
Registration :
https://escape.canceropole-paca.com/#/manifestation/subscription/19
Registration and abstract submission deadline is on Monday 19th of September 2022.
Best wishes,
On behalf of the organizing committee,
R. Margueron, A. Boré & M. Wassef
